Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib Combined With Radiotherapy for EGFR-Mutated Oligometastatic NSCLC
NCT07410611Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Feb 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of befotertinib in non-small cell lung cancer (NSCLC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Progression-Free Survival at 100 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07410611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410611.